- Home
- CCCC vs BGH Comparison
CCCC vs BGH Comparison
Compare CCCC & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- BGH
- Stock Information
- Founded
- CCCC 2015
- BGH 2012
- Country
- CCCC United States
- BGH United States
- Employees
- CCCC N/A
- BGH N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- BGH Investment Managers
- Sector
- CCCC Health Care
- BGH Finance
- Exchange
- CCCC Nasdaq
- BGH Nasdaq
- Market Cap
- CCCC 104.4M
- BGH 318.8M
- IPO Year
- CCCC 2020
- BGH N/A
- Fundamental
- Price
- CCCC $2.26
- BGH $15.82
- Analyst Decision
- CCCC Buy
- BGH
- Analyst Count
- CCCC 3
- BGH 0
- Target Price
- CCCC $12.00
- BGH N/A
- AVG Volume (30 Days)
- CCCC 1.6M
- BGH 61.5K
- Earning Date
- CCCC 07-31-2025
- BGH 01-01-0001
- Dividend Yield
- CCCC N/A
- BGH 10.06%
- EPS Growth
- CCCC N/A
- BGH N/A
- EPS
- CCCC N/A
- BGH N/A
- Revenue
- CCCC $39,783,000.00
- BGH N/A
- Revenue This Year
- CCCC N/A
- BGH N/A
- Revenue Next Year
- CCCC N/A
- BGH N/A
- P/E Ratio
- CCCC N/A
- BGH N/A
- Revenue Growth
- CCCC 98.56
- BGH N/A
- 52 Week Low
- CCCC $1.09
- BGH $11.92
- 52 Week High
- CCCC $7.66
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- CCCC 63.62
- BGH 79.80
- Support Level
- CCCC $1.36
- BGH $15.58
- Resistance Level
- CCCC $2.17
- BGH $15.78
- Average True Range (ATR)
- CCCC 0.15
- BGH 0.12
- MACD
- CCCC 0.05
- BGH 0.03
- Stochastic Oscillator
- CCCC 67.11
- BGH 99.42
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.